Otsuka Holdings Co. (OTSKY) 14.2500 $OTSKY
Atrial Fibrillation - Pipeline Review, H1 2014
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx455/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ARCA biopharma, Inc. - Armetheon, Inc. - Cardiome Pharma Corp - Daiichi Sankyo Company, Limited - Gilead Sciences, Inc. - HUYA Bioscience International, LLC - Isis Pharmaceuticals, Inc. - Laboratoires Pierre Fabre SA - Milestone Pharmaceuticals, Inc. - Nissan Chemical Industries, Ltd. - Nyken BV - Otsuka Holdings Co., Ltd. - Serodus ASA - Xention Limited Drug Profiles: - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - colchicine - bucindolol hydrochloride - vernakalant hydrochloride - budiodarone - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - onabotulinumtoxinA - XEN-D0101 - OPC-108459 - IKACh - XEN-D0104 - HBI-3000 - MSP-2017 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - SER-120 - budiodarone - Drug For Atrial Fibrillation - Adenosine A1 Agonist for Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/zrx455/atrial
Chronic Heart Failure - Pipeline Review, H1 2014: 22 Company and 30 Drugs Profiled
M2 - Wed May 07, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dlbpvz/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardioxyl Pharmaceuticals, Inc. - Celladon Corporation - Cyano Biotech GmbH - Fibrotech Therapeutics Pty. Ltd. - Hospira, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - MetrioPharm AG - NormOxys, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Palatin Technologies, Inc. - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Provasculon, Inc. - Sanofi - Scynexis, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. - miRagen Therapeutics, Inc. - t2cure GmbH Drug Profiles: - Neucardin - rivaroxaban - (AHU-377 valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - PL-3994 - CXL-1020 - tolvaptan - somatropin - Neucardin - finerenone - ivabradine - F-373280 - BMCs - cenderitide - OXY-111A - MGN-9103 - MP-2000 - BR-5489 - Small Molecule Allosteric Modulators Of SERCA2a - FT-011 - PB-1046 - SAR-296968 - PRV-0023 - Cyclophilin Inhibitory Compounds - etomoxir - PRV-0023 - Microginins ACE Inhibitors? Program - Vestiras For more information visit http://www.researchandmarkets.com/research/dl...onic_heart
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - Analysis of 26 Drug Profiles & 15 Companies
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9qdck3/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Sun Pharmaceutical Industries Limited - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Otsuka Holdings Co., Ltd. - Amakem NV - High Point Pharmaceuticals, LLC Drug Profiles - tafluprost - (tafluprost timolol maleate) - tafluprost - latanoprostene bunod - latanoprost - latanoprost - trabodenoson - PF-655 - SYL-040012 - RO-5093151 - latanoprost - aganepag isopropyl - simenepag isopropyl - AL-54478 - AMA-0076 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - brimonidine tartrate - ATS-8535 - Small Molecule for Glaucoma - ATS-907 - ATS-8535 For more information visit http://www.researchandmarkets.com/research/9qdck3/openangle
Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9rpd7/bipolar_disorder) has announced the addition of the "Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Dainippon Sumitomo Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Neurocrine Biosciences, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Delpor, Inc. - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - lurasidone hydrochloride - lurasidone hydrochloride - cariprazine - aripiprazole - quetiapine fumarate ER - ramelteon - Icariin - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - epoetin alfa - simvastatin - ketamine hydrochloride - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug For Cancer And Neurodegenerative Disease - lurasidone hydrochloride - Small Molecules for CNS Disorders - SKL-PSY - NP-202 - paliperidone - ebselen - GSK-3 Inhibitors for CNS and Metabolic disorders - risperidone - paliperidone - CNV-1061436 - KP-303 - GPR78 Antagonist for Bipolar Disorder and Schizophrenia - Small Molecule Targeting GPR50 for CNS and Metabolic Disorders - Ketamine Metabolites - Peptides For Bipolar Disorder - BRD-K98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/s9...r_disorder
Global Polycystic Kidney Disease Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fdfv7/polycystic_kidney) has announced the addition of the "Global Polycystic Kidney Disease Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Emergent BioSolutions Inc. - Plexxikon Inc. - Pfizer Inc. - Synta Pharmaceuticals Corp. - Metabolic Solutions Development Co. - IC-MedTech, Inc. - Endocyte, Inc. - ManRos Therapeutics - DiscoveryBiomed, Inc. - Otsuka Holdings Co., Ltd. - Kadmon Pharmaceuticals, LLC Drug Profiles - tolvaptan - tolvaptan - lanreotide acetate - bosutinib - KD-020 - KD-019 - GLG-302 - MSDC-0160 - MSDC-0602 - TNFR x TWEAKR - EC-0371 - Polycystic Kidney Disease Program - Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease - STA-2842 - RCMC-30 - Small Moleucles to Activate AMPK for Polycystic Kidney Disease - Drug For Polycstic Kidney Disease - Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drugs for Polycystic Kidney Disease - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - (Vitamin C Vitamin K3) For more information visit http://www.researchandmarkets.com/research/8f...tic_kidney
Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome
Liver Cirrhosis Global Clinical Trials Review, H2 2013 is Essential Reading for those in Medical Field
M2 - Tue Jan 14, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/rtmwq9/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Liver Cirrhosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Cirrhosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Cirrhosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Cirrhosis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Assistance Publique - Hopitaux de Paris - Astellas Pharma Inc. - Beijing Friendship Hospital - F. Hoffmann-La Roche Ltd. - Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - Genextra S.p.a. - Medical University of Vienna - Merck & Co., Inc. - Novartis AG - Okayama University - Otsuka Holdings Co., Ltd. - Pharmicell Co., Ltd. - Royal Prince Alfred Hospital - Sanofi - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/rt..._cirrhosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Schizophrenia Global Clinical Trials Review, 2013 Contains Essential Data for those in the Psychiatry Field
M2 - Thu Nov 21, 10:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/pphskq/schizophrenia) has announced the addition of the "Schizophrenia Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Schizophrenia Global Clinical Trials Review, H2, 2013" provides data on the Schizophrenia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizophrenia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizophrenia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated). Companies Mentioned: - Johnson & Johnson - Pfizer Inc. - AstraZeneca PLC - Eli Lilly and Company - Otsuka Holdings Co., Ltd. - Sumitomo Chemical Company, Limited - Merck & Co., Inc. - Bristol-Myers Squibb Company - H. Lundbeck A/S - AbbVie Inc. - The University of Maryland - Yale University For more information visit http://www.researchandmarkets.com/research/pp...izophrenia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Peptic Ulcers Global Clinical Trials Review, H2, 2013 Features the Key Drugs for Treating Peptic Ulcers
M2 - Wed Nov 20, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/p6twhl/peptic_ulcers) has announced the addition of the "Peptic Ulcers Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Peptic Ulcers Global Clinical Trials Review, H2, 2013" provides data on the Peptic Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Peptic Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peptic Ulcers. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - AstraZeneca PLC - Takeda Pharmaceutical Company Limited - Clinical Trial Overview of Takeda Pharmaceutical Company Limited - Pozen, Inc. - Clinical Trial Overview of Pozen, Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Zuventus Healthcare Ltd - Zeria Pharmaceutical Co Ltd - Otsuka Holdings Co., Ltd. - Eisai Co., Ltd. - Daiichi Sankyo Company, Limited - Chinese University of Hong Kong - Department of Health, South Africa - National Taiwan University Hospital - The Catholic University of Korea - Yokohama City University - Odense University Hospital - University of California, San Francisco - Keio University - Hamamatsu University School of Medicine - Samsung Medical Center For more information visit http://www.researchandmarkets.com/research/p6...tic_ulcers About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Finkelstein Thompson LLP Announces Investigation of Astex Pharmaceuticals, Inc. Buyout
Business Wire - Thu Sep 05, 10:24AM CDT
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex" or "the Company"
, concerning the Company's proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) ("Otsuka" . Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each share of Astex common stock they own. The total transaction is valued at approximately $886 million. At least one analyst has set a target price of $13.00 for Astex shares.
Research and Markets: Supplement Market in the US 2012-2016 with NBTY Inc., Otsuka Holdings Co. Ltd., and Perrigo Co. Dominating
Business Wire - Thu Aug 15, 1:32PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlh45q/supplement_market) has announced the addition of the "Supplement Market in the US 2012-2016" report to their offering.
Atrial Fibrillation - Pipeline Review, H1 2014
M2 - Wed May 07, 12:21PM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrx455/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ARCA biopharma, Inc. - Armetheon, Inc. - Cardiome Pharma Corp - Daiichi Sankyo Company, Limited - Gilead Sciences, Inc. - HUYA Bioscience International, LLC - Isis Pharmaceuticals, Inc. - Laboratoires Pierre Fabre SA - Milestone Pharmaceuticals, Inc. - Nissan Chemical Industries, Ltd. - Nyken BV - Otsuka Holdings Co., Ltd. - Serodus ASA - Xention Limited Drug Profiles: - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - colchicine - bucindolol hydrochloride - vernakalant hydrochloride - budiodarone - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - onabotulinumtoxinA - XEN-D0101 - OPC-108459 - IKACh - XEN-D0104 - HBI-3000 - MSP-2017 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - SER-120 - budiodarone - Drug For Atrial Fibrillation - Adenosine A1 Agonist for Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/zrx455/atrial
Chronic Heart Failure - Pipeline Review, H1 2014: 22 Company and 30 Drugs Profiled
M2 - Wed May 07, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dlbpvz/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Bayer AG - Cardioxyl Pharmaceuticals, Inc. - Celladon Corporation - Cyano Biotech GmbH - Fibrotech Therapeutics Pty. Ltd. - Hospira, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - MetrioPharm AG - NormOxys, Inc. - Novartis AG - Otsuka Holdings Co., Ltd. - Palatin Technologies, Inc. - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Provasculon, Inc. - Sanofi - Scynexis, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. - miRagen Therapeutics, Inc. - t2cure GmbH Drug Profiles: - Neucardin - rivaroxaban - (AHU-377 valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - PL-3994 - CXL-1020 - tolvaptan - somatropin - Neucardin - finerenone - ivabradine - F-373280 - BMCs - cenderitide - OXY-111A - MGN-9103 - MP-2000 - BR-5489 - Small Molecule Allosteric Modulators Of SERCA2a - FT-011 - PB-1046 - SAR-296968 - PRV-0023 - Cyclophilin Inhibitory Compounds - etomoxir - PRV-0023 - Microginins ACE Inhibitors? Program - Vestiras For more information visit http://www.researchandmarkets.com/research/dl...onic_heart
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - Analysis of 26 Drug Profiles & 15 Companies
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9qdck3/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Quark Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Sun Pharmaceutical Industries Limited - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Otsuka Holdings Co., Ltd. - Amakem NV - High Point Pharmaceuticals, LLC Drug Profiles - tafluprost - (tafluprost timolol maleate) - tafluprost - latanoprostene bunod - latanoprost - latanoprost - trabodenoson - PF-655 - SYL-040012 - RO-5093151 - latanoprost - aganepag isopropyl - simenepag isopropyl - AL-54478 - AMA-0076 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - brimonidine tartrate - ATS-8535 - Small Molecule for Glaucoma - ATS-907 - ATS-8535 For more information visit http://www.researchandmarkets.com/research/9qdck3/openangle
Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9rpd7/bipolar_disorder) has announced the addition of the "Global Bipolar Disorder (Manic Depression) Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Dainippon Sumitomo Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Neurocrine Biosciences, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Delpor, Inc. - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - lurasidone hydrochloride - lurasidone hydrochloride - cariprazine - aripiprazole - quetiapine fumarate ER - ramelteon - Icariin - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - epoetin alfa - simvastatin - ketamine hydrochloride - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug For Cancer And Neurodegenerative Disease - lurasidone hydrochloride - Small Molecules for CNS Disorders - SKL-PSY - NP-202 - paliperidone - ebselen - GSK-3 Inhibitors for CNS and Metabolic disorders - risperidone - paliperidone - CNV-1061436 - KP-303 - GPR78 Antagonist for Bipolar Disorder and Schizophrenia - Small Molecule Targeting GPR50 for CNS and Metabolic Disorders - Ketamine Metabolites - Peptides For Bipolar Disorder - BRD-K98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/s9...r_disorder
Global Polycystic Kidney Disease Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8fdfv7/polycystic_kidney) has announced the addition of the "Global Polycystic Kidney Disease Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Emergent BioSolutions Inc. - Plexxikon Inc. - Pfizer Inc. - Synta Pharmaceuticals Corp. - Metabolic Solutions Development Co. - IC-MedTech, Inc. - Endocyte, Inc. - ManRos Therapeutics - DiscoveryBiomed, Inc. - Otsuka Holdings Co., Ltd. - Kadmon Pharmaceuticals, LLC Drug Profiles - tolvaptan - tolvaptan - lanreotide acetate - bosutinib - KD-020 - KD-019 - GLG-302 - MSDC-0160 - MSDC-0602 - TNFR x TWEAKR - EC-0371 - Polycystic Kidney Disease Program - Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease - STA-2842 - RCMC-30 - Small Moleucles to Activate AMPK for Polycystic Kidney Disease - Drug For Polycstic Kidney Disease - Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drugs for Polycystic Kidney Disease - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - (Vitamin C Vitamin K3) For more information visit http://www.researchandmarkets.com/research/8f...tic_kidney
Global Tourette Syndrome Therapeutic Pipeline Review 2014
M2 - Tue Apr 15, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/78vx5h/tourette_syndrome) has announced the addition of the "Tourette Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tourette Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tourette Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Tourette Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Tourette Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Tourette Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Tourette Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Tourette Syndrome - Companies Involved in Therapeutics Development - AstraZeneca PLC - Neurocrine Biosciences, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Auspex Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Psyadon Pharmaceuticals, Inc. Drug Profiles - aripiprazole - ecopipam hydrochloride - AZD-5213 - acetylcysteine - vigabatrin - valbenazine - seridopidine - vatiquinone - RP-5063 - SD-809 ER For more information visit http://www.researchandmarkets.com/research/78...e_syndrome
Liver Cirrhosis Global Clinical Trials Review, H2 2013 is Essential Reading for those in Medical Field
M2 - Tue Jan 14, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/rtmwq9/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Liver Cirrhosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Cirrhosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Cirrhosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Cirrhosis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Assistance Publique - Hopitaux de Paris - Astellas Pharma Inc. - Beijing Friendship Hospital - F. Hoffmann-La Roche Ltd. - Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - Genextra S.p.a. - Medical University of Vienna - Merck & Co., Inc. - Novartis AG - Okayama University - Otsuka Holdings Co., Ltd. - Pharmicell Co., Ltd. - Royal Prince Alfred Hospital - Sanofi - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/rt..._cirrhosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Schizophrenia Global Clinical Trials Review, 2013 Contains Essential Data for those in the Psychiatry Field
M2 - Thu Nov 21, 10:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/pphskq/schizophrenia) has announced the addition of the "Schizophrenia Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Schizophrenia Global Clinical Trials Review, H2, 2013" provides data on the Schizophrenia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Schizophrenia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Schizophrenia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated). Companies Mentioned: - Johnson & Johnson - Pfizer Inc. - AstraZeneca PLC - Eli Lilly and Company - Otsuka Holdings Co., Ltd. - Sumitomo Chemical Company, Limited - Merck & Co., Inc. - Bristol-Myers Squibb Company - H. Lundbeck A/S - AbbVie Inc. - The University of Maryland - Yale University For more information visit http://www.researchandmarkets.com/research/pp...izophrenia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Peptic Ulcers Global Clinical Trials Review, H2, 2013 Features the Key Drugs for Treating Peptic Ulcers
M2 - Wed Nov 20, 9:46AM CST
Research and Markets (http://www.researchandmarkets.com/research/p6twhl/peptic_ulcers) has announced the addition of the "Peptic Ulcers Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Peptic Ulcers Global Clinical Trials Review, H2, 2013" provides data on the Peptic Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Peptic Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peptic Ulcers. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - AstraZeneca PLC - Takeda Pharmaceutical Company Limited - Clinical Trial Overview of Takeda Pharmaceutical Company Limited - Pozen, Inc. - Clinical Trial Overview of Pozen, Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Zuventus Healthcare Ltd - Zeria Pharmaceutical Co Ltd - Otsuka Holdings Co., Ltd. - Eisai Co., Ltd. - Daiichi Sankyo Company, Limited - Chinese University of Hong Kong - Department of Health, South Africa - National Taiwan University Hospital - The Catholic University of Korea - Yokohama City University - Odense University Hospital - University of California, San Francisco - Keio University - Hamamatsu University School of Medicine - Samsung Medical Center For more information visit http://www.researchandmarkets.com/research/p6...tic_ulcers About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Finkelstein Thompson LLP Announces Investigation of Astex Pharmaceuticals, Inc. Buyout
Business Wire - Thu Sep 05, 10:24AM CDT
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex" or "the Company"
, concerning the Company's proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) ("Otsuka" . Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each share of Astex common stock they own. The total transaction is valued at approximately $886 million. At least one analyst has set a target price of $13.00 for Astex shares. Research and Markets: Supplement Market in the US 2012-2016 with NBTY Inc., Otsuka Holdings Co. Ltd., and Perrigo Co. Dominating
Business Wire - Thu Aug 15, 1:32PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlh45q/supplement_market) has announced the addition of the "Supplement Market in the US 2012-2016" report to their offering.
